NEOS Neos Therapeutics Inc.

1.85
+0.09  (+5%)
Previous Close 1.76
Open 1.76
Price To Book -61.67
Market Cap 92,001,009
Shares 49,730,275
Volume 303,953
Short Ratio
Av. Daily Volume 472,821

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Approval announced September 15, 2017.
NT-0201
Attention deficit hyperactivity disorder (ADHD)
Approved January 27, 2016.
Adzenys XR-ODT
Attention deficit hyperactivity disorder (ADHD)
Approval announced June 19, 2017.
Cotempla XR-ODT
Attention deficit hyperactivity disorder (ADHD)
Phase 1 trial to commence 1H 2020.
NT0502
Sialorrhea

Latest News

  1. Edited Transcript of NEOS earnings conference call or presentation 8-Aug-19 12:30pm GMT
  2. Neos Therapeutics (NEOS) Reports Q2 Loss, Misses Revenue Estimates
  3. Neos Therapeutics Reports Second Quarter 2019 Financial Results
  4. Neos Therapeutics to Host Second Quarter 2019 Financial and Operating Results Conference Call on August 8th, 2019
  5. Altimmune to acquire California company for up to $93M
  6. Acer Shares Down on FDA's CRL for Genetic Disorder Treatment
  7. Neos Therapeutics to Present at Two Upcoming June Conferences
  8. Neos Therapeutics to Present at the Jefferies 2019 Global Healthcare Conference
  9. Neos Therapeutics Enters Oversold Territory
  10. Edited Transcript of NEOS earnings conference call or presentation 9-May-19 12:30pm GMT
  11. Neos Therapeutics (NEOS) Reports Q1 Loss, Tops Revenue Estimates
  12. Neos Therapeutics: 1Q Earnings Snapshot
  13. Neos Therapeutics Reports First Quarter 2019 Financial Results
  14. Neos Therapeutics to Host First Quarter 2019 Financial and Operating Results Conference Call on May 9th, 2019
  15. Neos Therapeutics (NEOS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
  16. Implied Volatility Surging for Neos Therapeutics (NEOS) Stock Options
  17. Edited Transcript of NEOS earnings conference call or presentation 14-Mar-19 12:30pm GMT
  18. Neos Therapeutics Inc (NEOS) Files 10-K for the Fiscal Year Ended on December 31, 2018